Literature DB >> 22095142

Impact of cannabis treatment on the quality of life, weight and clinical disease activity in inflammatory bowel disease patients: a pilot prospective study.

Adi Lahat1, Alon Lang, Shomron Ben-Horin.   

Abstract

BACKGROUND AND AIMS: Inflammatory bowel disease (IBD) patients suffer from significant morbidity and diminished life quality. The plant cannabis is beneficial in various gastrointestinal diseases, stimulating appetite and causing weight gain. Our aims were to assess whether treatment with inhaled cannabis improves quality of life, disease activity and promotes weight gain in these patients.
METHODS: Patients with long-standing IBD who were prescribed cannabis treatment were included. Two quality of life questionnaires and disease activity indexes were performed, and patient's body weight was measured before cannabis initiation and after 3 months' treatment.
RESULTS: Thirteen patients were included. After 3 months' treatment, patients reported improvement in general health perception (p = 0.001), social functioning (p = 0.0002), ability to work (p = 0.0005), physical pain (p = 0.004) and depression (p = 0.007). A schematic scale of health perception showed an improved score from 4.1 ± 1.43 to 7 ± 1.42 (p = 0.0002). Patients had a weight gain of 4.3 ± 2 kg during treatment (range 2-8; p = 0.0002) and an average rise in BMI of 1.4 ± 0.61 (range 0.8-2.7; p = 0.002). The average Harvey-Bradshaw index was reduced from 11.36 ± 3.17 to 5.72 ± 2.68 (p = 0.001).
CONCLUSIONS: Three months' treatment with inhaled cannabis improves quality of life measurements, disease activity index, and causes weight gain and rise in BMI in long-standing IBD patients.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2011        PMID: 22095142     DOI: 10.1159/000332079

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  33 in total

Review 1.  Complementary Therapies in Inflammatory Bowel Diseases.

Authors:  Henit Yanai; Nir Salomon; Adi Lahat
Journal:  Curr Gastroenterol Rep       Date:  2016-12

2.  Should Medical Cannabis Administered by Inhalation Be Allowed for Hospitalized Patients?

Authors: 
Journal:  Can J Hosp Pharm       Date:  2018-06-28

Review 3.  Complementary and Alternative Medicine Strategies for Therapeutic Gut Microbiota Modulation in Inflammatory Bowel Disease and their Next-Generation Approaches.

Authors:  Abigail R Basson; Minh Lam; Fabio Cominelli
Journal:  Gastroenterol Clin North Am       Date:  2017-12       Impact factor: 3.806

4.  Therapeutic Use of Cannabis in Inflammatory Bowel Disease.

Authors:  Waseem Ahmed; Seymour Katz
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-11

Review 5.  The Role of Cannabis in the Management of Inflammatory Bowel Disease: A Review of Clinical, Scientific, and Regulatory Information.

Authors:  Arun Swaminath; Eric P Berlin; Adam Cheifetz; Ed Hoffenberg; Jami Kinnucan; Laura Wingate; Sarah Buchanan; Nada Zmeter; David T Rubin
Journal:  Inflamm Bowel Dis       Date:  2019-02-21       Impact factor: 5.325

6.  The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis.

Authors:  B Romano; F Borrelli; I Fasolino; R Capasso; F Piscitelli; Mg Cascio; Rg Pertwee; D Coppola; L Vassallo; P Orlando; V Di Marzo; Aa Izzo
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

7.  Cannabis Abuse Is Increasing and Associated with Increased Emergency Department Utilization in Gastroenterology Patients.

Authors:  John Gubatan; Kyle Staller; Kenneth Barshop; Braden Kuo
Journal:  Dig Dis Sci       Date:  2016-03-02       Impact factor: 3.199

Review 8.  Medical Comorbidity and Complications.

Authors:  Scott E Hadland; Leslie Renee Walker
Journal:  Child Adolesc Psychiatr Clin N Am       Date:  2016-04-12

Review 9.  [Efficacy, tolerability, and safety of cannabinoids in gastroenterology: A systematic review].

Authors:  M S Volz; B Siegmund; W Häuser
Journal:  Schmerz       Date:  2016-02       Impact factor: 1.107

10.  Substance Use Patterns Through Early Adulthood: Results for Youth With and Without Chronic Conditions.

Authors:  Lauren E Wisk; Elissa R Weitzman
Journal:  Am J Prev Med       Date:  2016-03-30       Impact factor: 5.043

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.